Impact of Immunotherapies on CNS Outcomes in People with HIV: Potential Benefits, Challenges and Risks
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Institute of Mental Health (NIMH) plans to issue a funding opportunity to support biphasic research focused on the effects of HIV immunotherapies on central nervous system (CNS) outcomes in individuals living with HIV. The initiative aims to generate critical evidence on whether these therapies can effectively target persistent HIV within the CNS while minimizing potential neurotoxicity and neuroinflammation. Emphasis is placed on overcoming CNS-specific challenges, including blood-brain barrier penetration and compartmentalized viral behavior, to foster sustained viral remission throughout the body and improve cognitive and neurological health in people affected by HIV. Researchers with expertise in the intersection of HIV immunotherapy and CNS viral reservoirs are encouraged to apply, with the opportunity structured under the R21/R33 funding mechanism. The notice is intended to provide ample time for applicants to establish collaborative partnerships and develop responsive research proposals. The goal is to deepen understanding of the mechanisms, advantages, and risks of HIV immunotherapies within the CNS, ultimately supporting innovative strategies for long-term neurological well-being and viral control in HIV-positive populations.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
The National Institute of Mental Health (NIMH) intends to publish a notice of funding opportunity (NOFO) to solicit biphasic research applications to evaluate the impact of HIV immunotherapies on central nervous system (CNS) outcomes in people with HIV and to identify mechanisms, benefits, and risks associated with their use in the CNS compartment. The primary goal is to generate evidence that informs whether HIV immunotherapies can safely and effectively target CNS HIV persistence while minimizing neurotoxicity and neuroinflammation. By addressing CNS-specific barriers such as blood brain barrier penetration, compartmentalized viral dynamics, and immune-mediated effects, this NOFO will support the development of strategies that contribute to sustained virologic remission across anatomical compartments and improve long-term neurologic and cognitive outcomes in people with HIV. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Investigators with expertise and insights into the impact of HIV immunotherapies on the CNS and viral reservoirs are strongly encouraged to apply to this new NOFO. This NOFO will utilize the R21/R33 activity code.
